Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, ...

Recludix Pharma, a leader in the discovery of inhibitors for challenging targets in inflammatory disease, today announced a ...

PRESS RELEASE AB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLION Paris, May 23, 2025, 8am CET AB Science S.A. (the “Company” or “AB Science”, Euronext – ...

DelveInsight’s Peritoneal Cancer Pipeline report depicts a robust space with 55+ active players working to develop 60+ ...

A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS, INCLUDING MULTIPLE ...

PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros as of ...

The story of chronic itch and its impact on quality of life is one dermatologists have heard often. Until recently, treatment ...

Hoth Therapeutics announces positive preclinical results for HT-KIT, a precision antisense therapy targeting rare and aggressive KIT-driven cancers: New York Wednesday, May 14, 20 ...

The innate immune system: Components of the innate immune system are being recognized to play a role in MS. Masitinib is a mast cell inhibitor currently being studied. LINGO-1, Notch and Wnt have ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...